Ionis Pharmaceuticals, Inc.
Clinical trials sponsored by Ionis Pharmaceuticals, Inc., explained in plain language.
Ionis Pharmaceuticals, Inc.
IONS
NASDAQ
A biopharmaceutical company developing RNA-targeted therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise in preventing hereditary swelling attacks Results expected Dec 2026 (estimated)
- New drug shows promise for dangerous fat levels in blood Results expected Mar 2027 (estimated) May already have reported ↗
- Experimental drug ION717 aims to slow fatal brain disease Results expected Apr 2027 (estimated)
- New hope for rare fat disorder: safety trial of olezarsen underway Results expected Jun 2027 (estimated) May already have reported ↗
- New drug aims to unlock speech in angelman syndrome Results expected Aug 2027 (estimated)